Completed OBSERVATIONAL NCT04600388

Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine

Retrospective, Observational Survey Study to Assess the Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine

Sponsor: Theranica

Conditions Menstrual Migraine

Interventions Nerivio

Updated 4 times since 2020 Last updated: Dec 3, 2020 Started: Sep 9, 2020 Primary completion: Nov 1, 2020 Completion: Nov 10, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04600388, this observational or N/A phase trial focuses on Menstrual Migraine and remains completed. Sponsored by Theranica, it has been updated 4 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed

Status: Recruiting → Completed
Nov 2020 — Jan 2021 [monthly]

Recruiting

First recorded

Sep 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Theranica

Data source: Theranica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Poughkeepsie, United States